biosimilar filgrastim treatment. Less than one-third (29.8%) of the patients experienced C1 adverse event that was at least potentially related to biosimilar filgrastim treatment.
Conclusions: Biosimilar filgrastim was effective and well-tolerated in both the primary and secondary prophylactic setting in patients undergoing chemotherapy for solid tumors and hematological malignancies.
INTRODUCTION
Chemotherapy-induced neutropenia (CIN) is a common and serious complication of myelosuppressive chemotherapy [1] .
Neutropenia is associated with life-threatening infections and may delay the chemotherapy schedule, having a negative impact on early and long-term outcomes [2] . It is associated with significant morbidity and mortality, and may increase the overall cost of providing cancer therapy [3] . The results of three large-scale studies demonstrated that primary prophylaxis with a granulocyte-colony stimulating factor (G-CSF) significantly reduces the incidence of febrile neutropenia (FN) resulting from cytotoxic chemotherapy [4] [5] [6] . Thus, G-CSF products reduce the risk of infectious complications and with it, the consequent loss of therapeutic options, which may result from neutropenia [7] . The use of a G-CSF plus antibiotics may reduce hospitalization time and improve the ability to achieve neutrophil recovery in individuals with chemotherapy-induced FN [8] . Since the use of biosimilar filgrastim has not yet been sufficiently documented in the context of day-to-day medical practice, the goal of the VENICE study, (i.e., Compatibility of Nivestim with Cytotoxic Chemotherapy in the Treatment of Malignant Diseases) (ClinicalTrials.gov identifier, NCT01627990) was to assess the tolerability, safety and efficacy of prophylactic biosimilar filgrastim to reduce the duration of neutropenia and the incidence of FN in patients receiving cytotoxic cancer chemotherapy [12] . The VENICE study was a multicenter, prospective, longitudinal, observational study designed to evaluate the use of biosimilar filgrastim in 'real-world' clinical practice.
METHODS
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was not required from patients as this was a non-interventional observational trial.
Patient Population
The study enrolled children and adults of either gender with solid or malignant hematological tumors who were scheduled to undergo prophylactic treatment with biosimilar filgrastim (Nivestim) to shorten the duration of a neutropenia, or to prevent the occurrence of chemotherapy-induced FN. Reasons for exclusion from the study included chronic myeloid leukemia or myelodysplastic syndrome, hypersensitivity to any component of the biosimilar filgrastim product, not undergoing chemotherapy, or being treated curatively with G-CSF.
Primary Outcome Measures
The primary objective was to assess the tolerability, safety and efficacy of prophylactic treatment using biosimilar filgrastim in patients receiving cytotoxic chemotherapy for cancer, with an emphasis on patients undergoing in-patient treatment.
Secondary Outcome Measures
The secondary objectives were to describe the characteristics of patients being treated with biosimilar filgrastim; the treatment modalities using biosimilar filgrastim; and the characteristics of participating physicians and their prescribing practices with regard to G-CSF.
Subgroups
Patients were stratified according to age Other tumor types are summarized in Table 4 . Based on the TNM classification system, the majority of solid tumors were small, low-grade cancers with no metastasis, although they ranged from Stage I to Stage IV.
Chemotherapy
The goal of chemotherapy for all patients at enrollment was adjuvant (49%) or curative (31.9%) ( Table 5) ; with treatment being predominantly curative among patients with hematological malignancies (64.6%), but predominantly adjuvant among patients with breast cancer (63.1%). Among those with other solid tumors, the goal was adjuvant (31.4%) or curative therapy (29.5%).
For most patients, the planned chemotherapy was first line treatment (63.5%) and was similar across the tumor subgroups During follow-up visits, for the majority of patients (95.6%) there had been no change in chemotherapy dose due to FN. For two patients (0.5%) the chemotherapy was discontinued due to FN and for four patients (1.0%) the chemotherapy dose was reduced due to FN. For the majority of patients (96.9%) the chemotherapy cycle following the first biosimilar filgrastim treatment was not delayed due to FN. For three patients (0.8%), the chemotherapy was delayed following the first biosimilar filgrastim treatment. 
Hematologic Laboratory Values
Median hemoglobin and thrombocyte values in all tumor subgroups remained relatively 
Infections
Among patients for whom infection data were collected, 11.3% had an infection at first visit, 13.1% had an infection at the follow-up visit and 14.9% of the patients had an infection at a later chemotherapy cycle. Bacterial and viral infections were most frequently reported.
Adverse Events
In the course of the study, 29.8% of patients experienced C1 AE that was at least potentially related to biosimilar filgrastim treatment (Table 9 ). The treatment related AEs reported most frequently were musculoskeletal and connective tissue disorders (12.3%) with the preferred term (PT) bone pain (7.6%); general disorders and administration site conditions (9.9%) with the PTs mucosal inflammation (3.4%) and fatigue (3.1%); and blood and lymphatic system disorders (9.2%) with the PTs neutropenia (6.5%) and leukopenia (4.5%). During the study, eight patients (2.1%) reported serious adverse events (SAE) ( Table 10 ) that were considered as potentially related to treatment of which one patient died with an SAE with insufficient information to define possible relationship to treatment.
Less than one percent (0.8%) of patients had a delay in their chemotherapy due to FN after the first biosimilar filgrastim treatment and for 4.7% of patients, the chemotherapy in any subsequent cycle was delayed because of neutropenia. Reduction of the chemotherapy dose after first biosimilar filgrastim treatment due to FN was reported for 1% of patients and reduction of the chemotherapy dose in any subsequent cycle due to neutropenia was reported for 4.7% of patients.
Patient-Reported Data
The majority of patients administered the biosimilar filgrastim injection themselves at both treatment visits (77.7% at first visit and 68.6% at last visit). On a scale of very difficult to confirmed the similarity between biosimilar filgrastim and the reference product Neupogen [27, 28] and an extensive characterization study assessed the physiochemical similarity of biosimilar filgrastim to Neupogen [29] .
Samples were analyzed for physicochemical properties, molecular characteristics, purity and biological activity. They were also compared after long-term storage to evaluate their degradation impurity profiles. Biosimilar filgrastim and Neupogen were shown to have comparable physicochemical properties, molecular characteristics, purity and biological activity.
A phase III double-blind study demonstrated the bioequivalence of biosimilar filgrastim and Neupogen in patients with breast cancer treated with doxorubicin and docetaxel in the neoadjuvant/adjuvant or first-line metastatic setting [30] . Among patients randomized to receive biosimilar filgrastim (n = 184) and Neupogen (n = 95), the mean duration of severe neutropenia in Cycle 1 was similar for biosimilar filgrastim (1.6 days; n = 165) and Neupogen [13] . Additionally, age is a risk factor [13] and justifies the prophylactic treatment of G-CSF. The median age was 61 and 39% of the patients were [65 years old.
The limitations of this study include that it is non-interventional, observational and lacks a blinded control. Additionally, a weakness is the lack of data captured, specifically regarding the chemotherapy regimens and severity of FN.
The use of biosimilar filgrastim according to the label in the VENICE observational study was effective and well-tolerated in both the primary and secondary prophylactic setting in patients undergoing CT for solid tumors and hematological malignancies. The rate neutropenia observed (Table 10) 
